.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
NICE-SUGAR was a large randomised trial that compared intensive glucose control with conventional glucose management in more than 6,000 critically ill adults. The intensive strategy targeted blood glucose levels around 81–108 mg/dL, whereas the conventional strategy aimed for 180 mg/dL or less. The trial found higher 90-day mortality with intensive glucose control, establishing that tighter glycaemic targets could cause harm rather than benefit. Hypoglycaemia was also substantially more frequent in the intensive-treatment group. The study changed practice because it demonstrated the importance of separating biologic plausibility from clinical outcomes. Earlier studies had suggested that normalising glucose might protect critically ill patients, but NICE-SUGAR showed that aggressive insulin treatment carries its own risks and does not translate into improved survival. For bedside care, the practical implication is to avoid extremes: uncontrolled hyperglycaemia is undesirable, but pursuing near-normal glucose with intensive insulin therapy can create dangerous hypoglycaemia and treatment burden. The trial remains foundational when interpreting newer studies of metabolic management, nutrition and insulin protocols. It also illustrates a recurring ICU lesson: targets that look attractive in isolation should be tested against patient-centred outcomes before becoming routine standards.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
NICE-SUGAR was a large randomised trial that compared intensive glucose control with conventional glucose management in more than 6,000 critically ill adults. The intensive strategy targeted blood glucose levels around 81–108 mg/dL, whereas the conventional strategy aimed for 180 mg/dL or less. The trial found higher 90-day mortality with intensive glucose control, establishing that tighter glycaemic targets could cause harm rather than benefit. Hypoglycaemia was also substantially more frequent in the intensive-treatment group. The study changed practice because it demonstrated the importance of separating biologic plausibility from clinical outcomes. Earlier studies had suggested that normalising glucose might protect critically ill patients, but NICE-SUGAR showed that aggressive insulin treatment carries its own risks and does not translate into improved survival. For bedside care, the practical implication is to avoid extremes: uncontrolled hyperglycaemia is undesirable, but pursuing near-normal glucose with intensive insulin therapy can create dangerous hypoglycaemia and treatment burden. The trial remains foundational when interpreting newer studies of metabolic management, nutrition and insulin protocols. It also illustrates a recurring ICU lesson: targets that look attractive in isolation should be tested against patient-centred outcomes before becoming routine standards.
Today
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
6 days back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back
